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Background: Prostate vaporization and enucleation is a novel treatment option for bladder outlet obstruction
caused by benign prostate enlargement. This surgical technique, however, has not yet been standardized. We
present our findings of using a high-power thulium laser to accomplish vapoenucleation of the prostate (ThuVEP).
Methods: We prospectively collected and analyzed data from 29 patients who underwent ThuVEP between August
2010 and May 2012. The control group included 30 patients who underwent traditional transurethral resection of
the prostate (TURP). Operative variables, patient profiles, preoperative and postoperative urine flow rates, prostate
volume (measured using transrectal ultrasonography), and the international prostate symptom score (IPSS) were
recorded and analyzed using a two-tailed Student’s t-test and analysis of variance.
Results: The ages (mean ± SD) of the patients were 76.1 ± 9.4 and 72.6 ± 7.4 years (p = 0.28) in the ThuVEP and TURP
groups, respectively. The average urinary flow rates before and 12 months after the operation (volume/maximum flow/
average flow) were 243.3/10.5/5.0 and 302.8/17.6/9.4 (in mL, mL/s, mL/s, respectively) in the ThuVEP group and 247.2/
10.8/4.6 and 369.9/20.8/12.0, respectively, in the TURP group. Preoperative and postoperative IPSSs were 17.1 ± 5.0 and
6.5 ± 3.8, respectively, in the ThuVEP group and 18.2 ± 4.5 and 6.2 ± 3.3, respectively, in the TURP group. The mean ratio
of the estimated postoperative residual prostate volume to the preoperative total volume was 0.47 (p = 0.449) in both
groups. The overall complication rate was 20.7% in the ThuVEP group and 30.0% in the TURP group.
Conclusions: One year of follow-up showed that ThuVEP and TURP effectively alleviated subjective and objective
voiding symptoms with a low rate of complications. Thus, vapoenucleation using a high-power laser is feasible in
elderly patients.
Trial registration: ISRCTN registry with study ID ISRCTN52339705. Date assigned: 06/03/2015.
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Benign prostate enlargement (BPE) with lower urinary
tract symptoms is a commonly observed condition in
the daily clinical practice of urologists, especially those
treating an aging male population. Surgical intervention
is indicated for patients who develop complications asso-
ciated with bladder outlet obstruction. Acute urinary* Correspondence: tplin63@gmail.com
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unless otherwise stated.retention is the most frequently reported complication,
occurring in 0.5–6.5% of patients [1]. The likelihood of a
male patient requiring transurethral resection of the
prostate (TURP) increases by 6, 14, and 18 times with
each decade of life after 59 years of age [2].
Surgical interventions and second-line measures are the
treatments of choice for high-risk patients [3]. Surgical
intervention is believed to have the most significant influ-
ence on the natural course of BPE and on preventing
complications [4]. Surgical interventions include TURP
(monopolar or bipolar) and laser treatment of the prostate,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(HoLEP), green light laser, and thulium laser [5].
Several studies have shown that TURP is the most
common, widely performed, effective, and cost-efficient
treatment to date [5-7]. Although TURP is associated
with low morbidity [8], we should explore techniques
other than TURP that have even lower morbidity rates.
HoLEP is the most commonly performed surgical inter-
vention in recent decades, and the improvements in uro-
dynamic parameters with this technique are comparable
to those obtained with other techniques when performed
by experienced surgeons [9]. Krambeck et al. showed a
satisfactory outcome and low morbidity with HoLEP [10].
The over-deobstruction achieved by HoLEP, however,
might induce postoperative incontinence at an early stage
[10]. Because of a steep learning curve, the adoption rate
for this technique is low, and only a few studies on large
series of patients have been performed in limited centers
[11,12]. The learning curve may be prolonged, and 50
cases are required for a surgeon to obtain an outcome that
is comparable to that reported in the literature [13].
Thulium laser has several theoretical advantages over
the holmium laser (e.g., rapid vaporization and coagula-
tion ability, improved spatial beam quality, precise tissue
incision) [14,15]. Bach et al. presented the first study on
thulium:yttrium aluminum garnet (Tm:YAG) laser prosta-
tectomy using the vaporesection technique with a 70-W
Tm:YAG laser [16]. Shao et al. reported less blood loss in
the Tm:YAG group, and the outcome in this group was
similar to that observed in the group that underwent enu-
cleation of the prostate using the Ho:YAG laser [17].
Xia et al. reported the first prospective randomized
study comparing thulium laser resection with the
prostate-tangerine technique (TmLRP-TT) and the stand-
ard TURP for symptomatic BPE with a 50-W instrument
[18]. Both groups showed significant improvement in sub-
jective symptom scores and urodynamic parameters.
TmLRP-TT was significantly superior to TURP in terms of
duration of catheterization, duration of hospitalization, and
decrease in hemoglobin level [19]. The aforementioned
thulium laser series with the Tm:YAG laser (RevoLix®; LISA
Laser Products, Katlenburg, Germany) showed promis-
ing results. With the advancements in their technology,
thulium lasers with higher energy output are now available.
An example is the Quanta System Cyber Th:YAG laser.
This new generation of Th:YAG lasers offers a maximum
energy output of 150 W.
To our knowledge, the present study is the first pro-
spective nonrandomized trial of vapoenucleation using the
Cyber Th:YAG laser versus TURP with a 1-year follow-up.
Methods
After receiving approval from the institutional review
board of the Taipei Veterans General Hospital (VGHIRBNo. 201007014IC), we recruited patients between
August 2010 and May 2012 who had BPE that required
surgical intervention. All consents were obtained with
the method of written. The study was designed as a pro-
spectively nonblind randomized trial. It included 59 pa-
tients. The Th:YAG laser vapoenucleation (ThuVEP)
group included 29 patients and the TURP group had 30
patients. Informed consents for participation were ob-
tained from the participants.
The inclusion criteria were an international prostate
symptom score (IPSS) >7, maximum urinary flow rate
(Qmax) <15 mL/s, and normal level of age-specific
prostate-specific antigen (PSA) [20]. Patients with abnor-
mal levels of age-specific PSA or positive findings on
digital rectal examination underwent transrectal ultra-
sonography (TRUS)-guided biopsy to rule out prostate
cancer. Ten patients underwent TRUS-guided biopsy be-
fore the operation. To ensure intraoperative safety, we
asked the patients to discontinue all anticoagulants ex-
cept low-dose aspirin.
Before the operation, we evaluated the IPSS and qual-
ity of life score (QoLs) in each patient. Each was admin-
istered the five-item international index of erectile
function (IIEF-5) questionnaire. Prostate volume (V1) was
measured using TRUS and the prolate ellipsoid volume
formula. The postvoid residual (PVR) urine volume was
measured using bladder scans and uroflowmetry (UFR).
The patients were placed in the lithotomy position
under spinal anesthesia. A single surgeon (T.P.L.) per-
formed all of the ThuVEP procedures. TURP was per-
formed by three surgeons. We used 150-W thulium lasers
(Quanta Thulium Surgical Laser System: Cyber TM;
Quanta Systems, Solbiate Olona, Italy) coupled with a 26-
Fr resectoscope sheath (No. A22040A; Olympus, Tokyo,
Japan) for this procedure. Energy was delivered via 550-
mm end-firing fibers.
The technique utilized in the ThuVEP group was similar
to that used for trilobular HoLEP [21]. Briefly, we initiated
the procedure by making two Turner–Warwick-like inci-
sions in the 5 and 7 o’clock direction from the bladder
neck to the level of the verumontanum. The incision
continued to the surgical capsule. Then, we made a
third incision from the bladder neck to the level of the
verumontanum (the incision was not too distal) in the
12 o’clock direction. The three lobes were then enucle-
ated starting at the median lobe followed by the right
and left lobes. We did not perform a high degree of
blunt enucleation by using the beak of the resectoscope.
Instead, we used laser energy to incise and connect the
incisions performed previously. This procedure was fa-
cilitated using a guiding tube (No. A00561A; Olympus)
made specifically to elevate the incised prostate from
the plane between the adenoma and the surgical capsule
of the prostate (Figure 1). After all three lobes were
Figure 1 Overall laser system used. A: Quanta thulium surgical laser
system. B: View from the guiding tube. C: Procedure for laser
enucleation with the guiding tube. The median lobe was elevated
using the guiding tube. Thus, the surgical plan used tension to
further facilitate precise incision of the surgical capsule.
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omas were pushed into the bladder and morcellated
with a mechanical tissue morcellator, then the tissue is
evacuated from bladder. At the end of this procedure, the
operation site was irrigated with saline in all patients.
In the TURP group, TURP was performed using a
standard tungsten wire loop with a cutting current of160 W and a coagulating current of 80 W. All of the
prostate chips were removed using a Toomey evacuator.
At the end of both procedures, we inserted a 22-Fr
triple-lumen catheter into the bladder and initiated irriga-
tion until hematuria had decreased to a sufficient degree.
We performed postoperative histological examination of
all the tissues retrieved. Typically, the urethral catheter
was removed early on postoperative day 2 or 3 if severe
bleeding was not observed in the urine. The voiding pat-
tern was monitored for 1 day, and the patient was
discharged home.
The perioperative primary outcomes measured in the
two groups included the operative time (interval when
the resectoscope sheath was within the urethra), weight
of the resected tissue (actual weight of the tissue re-
trieved), decreased hemoglobin level, decreased serum
sodium level, duration of postoperative catheterization,
and postoperative hospital stay. We evaluated the IPSS,
QoLs, Qmax, and PVR urine in both groups at discharge
and at 3, 6, and 12 months after the operation. We re-
corded all perioperative complications. The IPSS was ob-
tained from the questionnaire and included two subscores:
voiding symptoms (incomplete emptying, intermittence,
weak stream, straining to void) and storage symptoms
(frequency, urgency, nocturia). In addition, preoperative
and postoperative sexual function was evaluated from the
IIEF-5 [22].
At 6 months after the operation, the prostate volume
of each patient was measured using a TRUS procedure
using an ultrasonography machine (BK Medical, Herlev,
Denmark) with a 7.5-MHz TRUS probe. The estimated
residual prostate volume (V2) was calculated as the vol-
ume of the entire gland using a prolate elliptical formula
(height × width × length × π/6) minus the central defect
(also calculated using the prolate elliptical formula). The
estimated residual prostate volume ratio was calculated
as V2/V1.
All measurement data for the two groups were statisti-
cally analyzed using a two-tailed Student’s t test. The data
are presented as the mean ± standard deviation (SD). The
scoring and questionnaire results were analyzed using ana-
lysis of variance (ANOVA). Statistical significance was
defined as p < 0.05.
Results
Baseline characteristics
Most of the baseline characteristics in the two groups
showed no differences (Table 1). However, the PVR in
the ThuVEP group was higher than that in the TURP
group (138.6 ± 127.7 vs. 90.9 ± 66.5, p = 0.040). The mean
age of the patients in our study was higher than that re-
ported in previous studies [19]. TRUS-guided biopsy was
performed in 15.3% of the patients before the procedure
because of increased levels of age-specific PSA.
Table 1 Baseline characteristics for the groups
Characteristic ThuVEP TURP p
Number 29 30
Age (years) 76.1 ± 9.4 72.6 ± 7.4 0.280
Anticoagulant* 15(51.7%) 6(20.0%) 0.011
BMI 23.9 ± 2.7 23.7 ± 3.4 0.281
PSA (ng/mL) 5.0 ± 5.4 8.3 ± 7.9 0.076
TRUS estimated weight (g) 57.2 ± 25.1 64.7 ± 32.5 0.758
IPSS 17.1 ± 5.0 17.8 ± 4.3 0.674
Charlson co-morbidity index 1.0 ± 1.0 1.6 ± 2.7 0.639
Qmax (mL/s) 10.5 ± 4.9 10.8 ± 4.7 0.728
PVR vol (mL)* 138.6 ± 127.7 90.9 ± 66.5 0.040
*Statistical difference.
BMI, body mass index; PSA, prostate-specific antigen; TRUS, transrectal ultrasound;
IPSS, international prostate symptom score; Qmax, maximum urinary flow rate;
PVR, post-void residual volume; ThuVEP, vapoenucleation of the prostate using a
high-power thulium laser; TURP, transurethral resection of the prostate.
Table 2 Perioperative data
Parameter ThuVEP TURP p
Resected weight (g)* 21.3 ± 14.3 37.4 ± 23.0 0.024
Preoperative hemoglobin level (g/dL) 12.9 ± 1.7 13.3 ± 1.6 0.587
Decrease in hemoglobin level (g/dL) 0.5 ± 1.3 0.5 ± 1.1 0.844
Decrease in serum sodium level (mmol/L) 0.3 ± 2.4 1.6 ± 2.0 0.468
Duration of catheterization (day)* 1.8 ± 0.5 2.3 ± 0.5 0.001
Total duration of hospitalization (days) 5.2 ± 1.9 5.2 ± 0.8 0.203
Postoperative duration of
hospitalization (days)*
3.0 ± 0.9 3.4 ± 0.7 0.032
Estimated residual prostate
volume ratio (V2/V1)
0.47 ± 0.17 0.47 ± 0.20 0.449
PSA ratio (before the operation/12
months after the operation)
2.4 ± 2.9 1.6 ± 1.0 0.180
ThuVEP, vapoenucleation of the prostate using a high-power thulium laser;
TURP, transurethral resection of the prostate; PSA, prostate-specific antigen.
The duration of catheterization and postoperative hospitalization showed
statistical differences. The estimated residual prostate volume (V2) was
calculated as the volume of the entire gland using prolate elliptical formula
(height × width × length × π/6) minus the central defect (also calculated using
the prolate elliptical formula). The estimated residual prostate volume ratio
was calculated as V2/V1.
(*Statistical difference).
Figure 2 International prostate symptom score (IPSS). No statistical
differences were observed between the two groups.
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The resected tissue was heavier in the TURP group than
in the ThuVEP group (37.4 ± 23.0 vs. 21.3 ± 14.3 g, p =
0.024), although the estimated residual prostate volume
ratio (0.47 ± 0.17 vs. 0.47 ± 0.20, p = 0.449) was the same
in the two groups. The duration of catheterization (1.8 ±
0.5 vs. 2.3 ± 0.5 days, p = 0.001) and postoperative hos-
pital stay (3.0 ± 0.9 vs. 3.4 ± 0.7 days, p = 0.032) were
shorter for the ThuVEP group than for the TURP group.
Other variables, such as total duration of hospitalization,
decrease in hemoglobin levels (0.5 ± 1.3 vs. 0.5 ± 1.1, p =
0.844), and decrease in serum sodium levels (0.3 ± 2.4 vs.
1.6 ± 2.0, p = 0.468) were not statistically different
(Table 2). In all, 96.3% patients in the ThuVEP group
and 93.3% in the TURP group completed the 1-year
follow-up study.
Follow-up of QoLs
The IPSS and QoLs in both groups had decreased sig-
nificantly postoperatively (Figure 2). The symptoms and
QoLs, however, began to improve and continued up to
12 months after the operation. The IPSS, including total
scores, subscores of voiding symptoms, and subscores of
storage symptoms, all displayed a similar trend of con-
tinuing to improve. There were no statistically signifi-
cant differences in these values between the two groups
(p = 0.551).
Follow-up of UFR and PVR urine volume
All UFR variables – voided volume, Qmax, mean flow
rate – improved significantly in both groups after the
operation (not all of the data are shown, Figure 3). The
preoperative PVR urine volume was significantly higher
in the ThuVEP group. The postoperative PVR urine vol-
ume markedly decreased in both groups, with nodifference observed in the PVR urine volumes 3 months
after the operation in the two groups (68.2 ± 37.5 vs.
69.5 ± 47.9, p = 0.648).
Complications
We used the modified Clavien classification system for
reporting TURP-related complications in our patients,
as proposed by Smith and Patel [23]. Six complications
were recorded among the 29 patients in the ThuVEP
group: 6.9% patients had grade I complications, and
13.8% had grade II complications. None of the patients
exhibited grade III–V complications. Nine complications
were recorded in the 30 TURP group patients. Grade I
complications were observed in 1.3% of patients and
Figure 3 Uroflowmetry (UFR). A: Maximum urinary flow rate (Qmax)
according to the UFR test data. No statistical differences were observed
in the two groups. B: Postvoid residual volume in the UFR test data. All
variables improved significantly in the two groups after the operation
without statistical differences at later follow-up examinations.
Table 3 Modified Clavien classification system for






Hematuria clot retention requiring bladder
irrigation/clot evacuation/catheter traction
0 1 (3.3%)
Catheter block because of retained TUR chip 0 0




Transient increase in the serum creatinine level 0 0
Lower urinary tract infection requiring antibiotics 0 0
Grade 2
Hemorrhage/hematuria requiring transfusion 4 (13.8%) 8 (26.7%)






Pulmonary embolism requiring anticoagulants 0 0
Grade 3
Extraperitoneal fluid collection caused by
subtrigonal catheter requiring endoscopic
catheter repositioning and surgical drainage
0 0
Grade 4
Acute myocardial infarction requiring
admission to the ICU
0 0






ThuVEP, vapoenucleation of the prostate using a high-power thulium laser;
TURP, transurethral resection of the prostate.
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observed in this group (Table 3).
Discussion
Surgical techniques used to treat bladder outlet ob-
struction include Tm:YAG vaporization of the prostate
(ThuVAP), Tm:YAG vaporesection of the prostate
(ThuVaRP), ThuVEP, and Tm:YAG laser enucleation of
the prostate (ThuLEP) [24].
The wavelength of thulium laser matches that of the
water absorption peak in tissue at 1.92 mm, which results
in sufficient hemostasis, a clear visual field, and rapid inci-
sion of the tissues with little thermal damage. Fried et al.
reported that continuous-wave 50-W thulium fiber laser
vaporized prostate tissue at a rate of 0.45 g/min [8].
Because of the high vaporization inherent in laser–tissue
interaction with thulium-YAG laser, the true resected
prostate volume was difficult to determine compared to
that with other enucleation prostatectomies or TURP. To
address this issue, we prospectively measured the prostate
volume by TRUS. The estimated residual prostate volume
was obtained by subtracting the volume of the entire pros-
tate from that of the central defect, which were calculated
using the values of the outer and inner dimensions, re-
spectively. Although the prostate volume differedsignificantly after resection, the residual volumes after both
approaches (ThuVEP and TURP) were not significantly dif-
ferent. The equal ratio of residual prostate volume was
supported by equal symptom improvement and urody-
namic improvement. Thus, the ratio of the postoperative
prostate volume to the preoperative prostate volume that
was estimated from TRUS-guided biopsy samples may bet-
ter predict symptom alleviation or urodynamic improve-
ment than tissue resected when ThuVEP is utilized.
HoLEP involves a three-lobe technique (median lobe
and lateral lobes) for enucleation of the prostate [21].
ThuLEP was introduced by Herrmann et al. [25]. Unlike
other techniques that involve determination of the surgical
capsule at the apex, this technique involves apical incision
of the prostatic tissue down to the surgical capsule. This
approach is further facilitated by the superior Th:YAG–
tissue interaction and higher vaporizing property. This ap-
proach did not compromise the deobstruction as shown
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toms. Also, this trend toward improvement was still
ongoing at the 12-month follow-up.
The perioperative morbidity associated with TURP de-
creased when the surgical equipment was modified.
However, the possibility of TUR syndrome, a common
complication, continues to exist. Our study showed that
the complication rate, blood transfusion rate, and de-
crease in the serum sodium and hemoglobin levels were
lower with ThuVEP than with other laser instruments or
TURP [26].
Laser surgery has been recommended because there is
less risk of sexual dysfunction. Xia et al. reported that
3.8% patients in the TmLRP-TT group and 14.6% pa-
tients in the TURP group had slightly reduced erectile
function at 12 months postoperatively [19]. Preopera-
tively, about 50% patients who underwent TmLRP-TT
and TURP had not had erections sufficient for inter-
course [19]. Because of the advanced age of the patients
in our study, we did not have a sufficient number of po-
tent patients before the operation in either group to as-
sess this point. Therefore, we were unable to compare
the theoretical complications of TUR surgery.
In previous studies, the intraoperative and postopera-
tive complications covered a wide extent of damage and
severity: clot retention; significant hematuria that pro-
longs hospitalization; open cystotomy to remove aden-
omas; myocardial infarction and atrial fibrillation that
require cardioversion; morcellator bladder injury; cere-
bral vascular accident; sepsis [10]. We used the modified
Clavien classification system to report and systematically
analyze the complications according to treatment [27].
This method has been adopted in various surgical disci-
plines as it has improved detection and avoided observa-
tion bias. Masumori et al. was the first to use the
Clavien classification system to report complications of
TURP. The overall perioperative morbidity was 15.8%,
including grade I (59.1%) and II (29.5%) complications,
those requiring interventions (2.3%, grade III), intensive
care unit (ICU) admission (6.8%, grade IV), and one
death (0.5%, grade V) [6].
We used the modified Clavien classification system to
classify our patients (Table 3). There were no high-grade
(grades III–V) complications in either group in our study.
Age and the Charlson co-morbidity index are inde-
pendent and highly significant (p < 0.001) predictors for
mortality [7]. Use of oral anticoagulants was regarded as
an independent factor for the outcome of TURP as it
was associated with significantly longer hospitalization
and higher rates of bladder clots, blood transfusions, late
hematuria, and thromboembolic events [28].
We prospectively recorded the above factors for our
patients (Table 1). A total of 35.6% of the patients in our
study took anticoagulants. These patients tended to beolder and had larger prostates with more tissue resected.
The blood transfusion rate in this study was higher than
that in our previous study, increasing from 2.2% to 4.2%
[19,26]. There was a minimal difference, however, in the
hemoglobin level before and after the operation (around
0.5 g/dL). These findings indicate that although the
thresholds for blood transfusion were low, they would
be permissible in these older, fragile patients.
We conducted a nonrandomized controlled study to
compare ThuVEP and TURP. We prospectively collected
the cohort data and systemically evaluated the Charlson
index for co-morbidity and complications reported ac-
cording to the modified Clavien classification. Our re-
sults showed that ThuVEP obtained equal and durable
symptomatic and urodynamic improvements at the 12-
month follow-up. Preoperative and postoperative TRUS
evaluation of prostate size indicated that a uniform
amount of tissue was excised. This was especially im-
portant in the ThuVEP group because the vaporization
rate of the tissue is high using thulium laser. Thus, the
tissue resected using ThuVEP cannot represent the exact
volume of the resected prostatic tissue.
Our study has several limitations. Most of the proce-
dures were performed by a single surgeon who was re-
sponsible for the entire ThuVEP group. Three surgeons
were responsible for the TURP group (T.P.L., Y.H.C.,
W.J.H.). Thus, a comparison of these two groups may be
subjected to bias. However, because all participating sur-
geons had engaged in their clinical practices for more
than 10 years, they had accrued surgical experience with
50 patients or more per year. Thus, the operator-related
bias was limited. Also, the follow-up duration was not
sufficiently long. The outcome of the procedure may dif-
fer after a longer follow-up. Finally, our study was not
randomized, which lowers the level of evidence-based
medicine. Thus, large-scale, prospective, and random-
ized studies are required to eliminate the possible bias
inherent to a nonrandomized study design.
Conclusions
The outcome of high-energy (150 W) ThuVEP in terms of
symptom alleviation and improved urodynamic parame-
ters was similar to that obtained using TURP. This laser
procedure is well tolerated, and enables efficient excision
and rapid organic vaporization. The results indicate the
feasibility of high-energy Th:YAG laser vapoenucleation
for the treatment of benign prostate hyperplasia.
Abbreviations
ThuVEP: Vapoenucleation of the prostate using high-power thulium laser;
TURP: Transurethral resection of the prostate; ANOVA: Analysis of variance;
BPE: Benign prostate enlargement; Tm: Thulium; YAG: Yttrium aluminum
garnet; PVR: Postvoid residual; UFR: Uroflowmetry.
Competing interests
The authors declare that they have no competing interests.
Chang et al. BMC Urology  (2015) 15:40 Page 7 of 7Authors’ contributions
Study conception and design: TPL, ATLL, KKC. Acquisition of data: TPL, YHC, WJSH,
ATLL. Analysis and interpretation of data: CHC. Drafting of manuscript: CHC.
Critical revision: TPL, ATLL. All authors read and approved the final manuscript.Acknowledgment
We thank Miss Hui-Chen Lee in the Division of Experimental Surgery for her
valuable assistance with the statistical analyses.
Author details
1Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan.
2Department of Urology, National Yang-Ming University School of Medicine,
Taipei, Taiwan. 3Shu-Tien Urological Science Research Center, Taipei, Taiwan.
4Department of Urology, Taipei Medical University Hospital, Taipei, Taiwan.
5Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical
University, Taipei, Taiwan.
Received: 5 July 2014 Accepted: 16 April 2015
References
1. Lo KL, Chan MC, Wong A, Hou SM, Ng CF. Long-term outcome of patients
with a successful trial without catheter, after treatment with an alpha-
adrenergic receptor blocker for acute urinary retention caused by benign
prostatic hyperplasia. Int Urol Nephrol. 2010;42:7–12.
2. Merrill RM, Hunter BD. The diminishing role of transurethral resection of the
prostate. Ann Surg Oncol. 2010;17:1422–8.
3. Robert G, Descazeaud A, de la Taille A. Lower urinary tract symptoms
suggestive of benign prostatic hyperplasia: who are the high-risk patients
and what are the best treatment options? Curr Opin Urol. 2011;21:42–8.
4. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC.
5-year outcome of surgical resection and watchful waiting for men with
moderately symptomatic benign prostatic hyperplasia: a department of
veterans affairs cooperative study. J Urol. 1998;160:12–6. discussion 6–7.
5. Hoekstra RJ, Van Melick HH, Kok ET, Ruud Bosch JL. A 10-year follow-up after
transurethral resection of the prostate, contact laser prostatectomy and
electrovaporization in men with benign prostatic hyperplasia; long-term
results of a randomized controlled trial. BJU Int. 2010;106:822–6.
6. Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T. The
12-year symptomatic outcome of transurethral resection of the prostate
for patients with lower urinary tract symptoms suggestive of benign
prostatic obstruction compared to the urodynamic findings before
surgery. BJU Int. 2010;105:1429–33.
7. Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, Shariat SF, et al.
Development and external validation of a highly accurate nomogram for
the prediction of perioperative mortality after transurethral resection of the
prostate for benign prostatic hyperplasia. J Urol. 2009;182:626–32.
8. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al.
Morbidity, mortality and early outcome of transurethral resection of the
prostate: a prospective multicenter evaluation of 10,654 patients. J Urol.
2008;180:246–9.
9. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR.
Holmium laser versus transurethral resection of the prostate: a randomized
prospective trial with 1-year followup. J Urol. 1999;162:1640–4.
10. Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000
holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol.
2010;183:1105–9.
11. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate
versus open prostatectomy for prostates greater than 100 grams: 5-year
follow-up results of a randomised clinical trial. Eur Urol. 2008;53:160–6.
12. Gnessin E, Mandeville JA, Lingeman JE. An update on holmium laser
enucleation of the prostate and why it has stood the test of time. Curr Opin
Urol. 2011;21:31–5.
13. Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas
R, et al. Holmium laser enucleation of prostate: outcome and complications
of self-taught learning curve. Urology. 2009;73:1042–8.
14. Fried NM, Murray KE. High-power thulium fiber laser ablation of urinary
tissues at 1.94 microm. J Endourol. 2005;19:25–31.
15. Fried NM. High-power laser vaporization of the canine prostate using a
110 w thulium fiber laser at 1.91 microm. Lasers Surg Med. 2005;36:52–6.16. Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ. RevoLix
vaporesection of the prostate: initial results of 54 patients with a 1-year
follow-up. World J Urol. 2007;25:257–62.
17. Shao Q, Zhang FB, Shang DH, Tian Y. Comparison of holmium and thulium
laser in transurethral enucleation of the prostate]. Zhonghua Nan Ke Xue.
2009;15:346–9.
18. Xia SJ, Zhang YN, Lu J, Sun XW, Zhang J, Zhu YY, et al. Thulium laser
resection of prostate-tangerine technique in treatment of benign prostate
hyperplasia. Zhonghua Yi Xue Za Zhi. 2005;85:3225–8.
19. Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus
standard transurethral resection of the prostate: a randomized prospective
trial. Eur Urol. 2008;53:382–9.
20. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N,
et al. Serum prostate-specific antigen in a community-based population of
healthy Japanese men: lower values than for similarly aged white men. Br J
Urol. 1995;75:347–53.
21. Gilling P. Holmium laser enucleation of the prostate (HoLEP). BJU Int.
2008;101:131–42.
22. Vroege JA. The sexual health inventory for men (IIEF-5). Int J Impot Res.
1999;11:177.
23. Smith RD, Patel A. Transurethral resection of the prostate revisited and
updated. Curr Opin Urol. 2011;21:36–41.
24. Bach T, Xia SJ, Yang Y, Mattioli S, Watson GM, Gross AJ, et al. Thulium: YAG
2 mum cw laser prostatectomy: where do we stand? World J Urol.
2010;28:163–8.
25. Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, et al.
Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical
prostatectomy with laser support. Introduction of a novel technique for the
treatment of benign prostatic obstruction. World J Urol. 2010;28:45–51.
26. Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ. Feasibility and
efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate.
World J Urol. 2009;27:541–5.
27. Morgan M, Smith N, Thomas K, Murphy DG. Is Clavien the new standard for
reporting urological complications? BJU Int. 2009;104:434–6.
28. Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, et al.
Impact of oral anticoagulation on morbidity of transurethral resection of the
prostate. World J Urol. 2011;29:211–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
